PCOS MICROBIOME

Polycystic ovary syndrome (PCOS) and the gut microbiome

Coordinatore	BAR ILAN UNIVERSITY    more  Organization address address: BAR ILAN UNIVERSITY CAMPUS city: RAMAT GAN postcode: 52900 contact info Titolo: Ms Nome: Estelle Cognome: Waise Email: send email Telefono: +972 35317439 Fax: +972 36353277
Nazionalità Coordinatore	Israel [IL]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2013-CIG
Funding Scheme	MC-CIG
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-06-01   -   2018-05-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	BAR ILAN UNIVERSITY  Organization address address: BAR ILAN UNIVERSITY CAMPUS city: RAMAT GAN postcode: 52900 contact info Titolo: Ms Nome: Estelle Cognome: Waise Email: send email Telefono: +972 35317439 Fax: +972 36353277	IL (RAMAT GAN)	coordinator	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The polycystic ovary syndrome (PCOS) consists of anovulation, acne, hirsutism (resulting from hyperandrogenism), and reversed serum LH to FSH ratio and two hallmarks that include low grade inflammation and insulin resistance. These features place women with PCOS as a group of patients related to the metabolic syndrome. Baranova et al. even stated that 'it seems appropriate to consider polycystic ovary syndrome as the ovarian manifestation of metabolic syndrome'. Following the known evidence on the involvement of the microbiota in inducing low grade inflammation, the involvement in insulin resistance, how the gut microbiota and diet affect each other and a recent study on the favorable effect of diet even in lean PCOS patients, it is tempting to study gut microbiota primarily in lean PCOS patients, since this would neutralize the effect of obesity and the metabolic syndrome. It is possible that gut microbiota population, as the relevant 'environment' of the patients, could bridge the gap and explains much of what has remained enigmatic in PCOS. This can also contribute significantly to treatment modalities, as interventions to alter gut microbial population profile have been shown to provide benefits in other situations.'